DECIPHERING THE IMPACT OF RAC1-SPTAN1 IN ARPKD CYSTOGENESIS USING MULTIFACETED MODELS

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/a08f62a0a5213af689e204d7becfd75f.pdf
DECIPHERING THE IMPACT OF RAC1-SPTAN1 IN ARPKD CYSTOGENESIS USING MULTIFACETED MODELS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Shohei
Kuraoka
Shohei Kuraoka skuraoka@kuh.kumamoto-u.ac.jp Kumamoto university Department of Pediatrics Kumamoto Japan * Massachusetts General Hospital Division of Nephrology Boston United States
Yuhei Higashi yhigashi@mgh.harvard.edu Massachusetts General Hospital Division of Nephrology Boston United States -
Suguru Saito Suguru.Saito2@cshs.org Cedars-Sinai Medical Center Department of Pathology and Laboratory Medicine Los Angeles United States -
Solmaz Pourgonabadi spourgonabadi@mgh.harvard.edu Massachusetts General Hospital Division of Nephrology Boston United States -
Honami Honjoh hhonjoh1@mgh.harvard.edu Massachusetts General Hospital Division of Nephrology Boston United States -
Sho Ishigaki Sho.Ishigaki@cshs.org Cedars-Sinai Medical Center Department of Pathology and Laboratory Medicine Los Angeles United States -
Peter Harris Harris.Peter@mayo.edu Mayo Clinic Division of Nephrology and Hypertension Rochester United States -
Lisa Satlin lisa.satlin@mssm.edu Icahn School of Medicine at Mount Sinai Department of Pediatrics New York United States -
Michifumi Yamashita Michifumi.Yamashita@csmc.edu Cedars-Sinai Medical Center Department of Pathology and Laboratory Medicine Los Angeles United States -
Ryuji Morizane rmorizane@mgh.harvard.edu Massachusetts General Hospital Division of Nephrology Boston United States - Harvard university Harvard Stem Cell Institute Cambridge United States